To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
3,014 Newest Publications of Expert Reviews
rss
matching the following criteria
Health technology assessment: a European collaboration
25-02-2011 | Zoltán Kaló; Zoltán Vokó, Expert Review of Pharmacoeconomics & Outcomes Research, 2011
A record number of more than 2900 professionals attended the 13th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research. ‘Health technology assessment: a European collaboration’ was the main theme of the congress. The scientific program included ...
Pharmacoeconomics of darunavir
25-02-2011 | Dwight S Fullerton; Erik Smets; Guy De La Rosa; Joseph M Mrus, Expert Review of Pharmacoeconomics & Outcomes Research, 2011
Darunavir boosted with ritonavir (DRV/r) in combination with other antiretrovirals (ARVs) was initially approved in 2006 for the treatment of HIV infection in ARV treatment-experienced adults and has subsequently been approved for use in treatment-naive adults in 2008. Clinical studies have ...
Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery
25-02-2011 | Sorrel E Wolowacz, Expert Review of Pharmacoeconomics & Outcomes Research, 2011
Dabigatran etexilate (DE) is a novel oral anticoagulant indicated for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement surgery. The majority of these patients receive some kind of thromboprophylaxis, most commonly low-molecular-weight heparin ...
News in brief
25-02-2011 | Expert Review of Pharmacoeconomics & Outcomes Research, 2011
Expert Review of Pharmacoeconomics & Outcomes Research , February 2011, Vol. 11, No. 1, Pages 5-7.
Correctly measuring drug development risk: a public policy imperative
25-02-2011 | John A Vernon; Joseph H Golec, Expert Review of Pharmacoeconomics & Outcomes Research, 2011
Expert Review of Pharmacoeconomics & Outcomes Research , February 2011, Vol. 11, No. 1, Pages 1-3.
Corrigendum
23-02-2011 | Expert Review of Anticancer Therapy, 2011
Expert Review of Anticancer Therapy , February 2011, Vol. 11, No. 2, Pages 323-324.
Acknowledgements
23-02-2011 | Expert Review of Anticancer Therapy, 2011
Expert Review of Anticancer Therapy , February 2011, Vol. 11, No. 2, Pages 321-321.
Dosimetric and clinical review of helical tomotherapy
23-02-2011 | Yi Rong; James S Welsh, Expert Review of Anticancer Therapy, 2011
As a modality for delivering rotational therapy, helical tomotherapy offers dosimetric advantages by combining a continuously rotating gantry with a binary multileaf collimator. Helical tomotherapy, embodied in the TomoTherapy® Hi-Art II® system, delivers intensity-modulated fan beams in a ...
Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence
23-02-2011 | Gennaro Daniele; Pasqualina Giordano; Antonella De Luca; Maria Carmela Piccirillo; Massimo Di Maio; Antoni ..., Expert Review of Anticancer Therapy, 2011
Bisphosphonates (BPs) are cornerstones in the treatment of patients with compromised skeletal integrity (either cancer related or not). However, a major indication for BPs use remains the treatment of patients with advanced cancer metastatic to the bone. Recently, several observations derived ...
Motherhood after breast cancer: searching for la dolce vita
23-02-2011 | Hatem A Azim; Fedro A Peccatori; Evandro de Azambuja; Martine J Piccart, Expert Review of Anticancer Therapy, 2011
Advances in the field of adjuvant therapy in breast cancer have led to significant improvements in breast cancer survival. This has resulted in a progressive decline in breast cancer-related mortality, such that in 2010 there were estimated to be 400,000 breast cancer survivors under the age ...
Netmeeting
